LeMaitre Vascular (LMAT) 2026 stock analysis: niche peripheral-vascular device market share and pricing power, the bolt-on acquisition playbook, aging-population demand as a defensive growth driver, the direct sales force model, and how LMAT avoids fights with Medtronic and BD.
Rayence (KRX:228850) 2026 stock outlook for US investors. A deep look at its intraoral sensor (IOS) leadership, CMOS versus TFT detector technology, the Vatech affiliate relationship, the 2025 pricing squeeze, foreign-stock tax mechanics, and KRW currency exposure.
Boditech Med (206640) stock outlook 2026. A deep, qualitative look at the razor-and-blade model behind this Korean point-of-care diagnostics maker: reader placement versus recurring cartridge sales, its 130-country distribution moat, post-COVID base-effect risk, currency exposure, and a peer comparison.
ATEC (Alphatec Holdings) stock outlook for 2026: how its integrated procedural platform of implants, EOS 3D imaging, and SafeOp neuromonitoring is taking spine-surgery share from Medtronic and Globus Medical, weighed against cash burn, litigation, and refinancing risk.
JVM Co. (054950) 2026 stock outlook. A qualitative deep dive into the ATDPS automated dispensing niche, razor-and-blade consumables economics, the Hanmi Science affiliation, European and US export growth, and the customer-concentration, FX, and slow-growth risks that define this Korean med-tech name.
AtriCure (ATRC) stock outlook 2026: a qualitative deep dive into the surgical Afib ablation and AtriClip left atrial appendage management business, the guideline tailwind driving adoption, why the company still runs a net loss, and the pulsed field ablation competitive threat.
Integra LifeSciences (IART) stock outlook for 2026. A deep qualitative look at its neurosurgery dura replacements and CSF shunts, collagen skin-regeneration matrices, reconstructive portfolio, the niche surgical moat, recall and quality (QC) manufacturing-normalization execution risk, and how it stacks up against SYK, ZBH, and GMED.
IRTC (iRhythm Technologies) stock outlook for 2026. A deep, qualitative look at the Zio long-term ECG patch and AI arrhythmia analysis, ambulatory-monitoring standardization, Medicare reimbursement risk, competition from Boston Scientific, and the path to durable profitability.
NARI (Inari Medical) 2026 stock outlook. A deep qualitative look at the FlowTriever and ClotTriever mechanical thrombectomy franchise, the venous thromboembolism (VTE) TAM and penetration story, competition from Penumbra and Boston Scientific, reimbursement dynamics, and what Stryker's strategic interest means for investors.
Haemonetics (HAE) stock outlook for 2026: the NexSys plasma razor-and-blade consumables model, CSL and large-customer concentration risk, contract transitions, and the Hospital diversification thesis (TEG hemostasis, vascular closure) with bull, base, and bear scenarios.
Dio Corp (039840) 2026 outlook: the DIOnavi full-digital implant moat and export growth versus the China VBP pricing shock, US channel, FX, and competition from Osstem, Dentium, Straumann.
INSP (Inspire Medical Systems) 2026 stock outlook. A deep qualitative look at the hypoglossal nerve stimulation implant for obstructive sleep apnea (OSA), the razor-and-blade growth model, the clinical-evidence and reimbursement and hospital-adoption moat, CPAP-intolerant market penetration, the GLP-1 weight-loss threat, Nyxoah competition, and the path to profitability.
i-SENS (099190) 2026 stock outlook. A deep qualitative look at the self-monitoring blood glucose (BGM) cash cow, the continuous glucose monitor (CGM) localization and reimbursement growth option, the electrochemical biosensor platform, overseas OEM supply, competition from Abbott Libre and Dexcom, CGM investment losses, and currency risk.
GKOS (Glaukos) 2026 stock outlook. A deep qualitative look at its glaucoma MIGS leadership with iStent, the iDose sustained drug-delivery pivot, the Epioxa corneal-disease pipeline, and the reimbursement, competition, and cash-burn growth-stock risks.
PEN (Penumbra) 2026 stock outlook. A qualitative deep dive into aspiration thrombectomy for stroke, peripheral CAVT, the single-use catheter razor-and-blade model, recall and valuation risk, and Stryker and Medtronic competition.
Vatech (KOSDAQ 043150) 2026 stock outlook for foreign investors. A qualitative deep dive into its 3D cone-beam CT, panoramic X-ray and intraoral scanner lineup, the analog-to-digital dentistry shift, AI-reading software and consumable recurring revenue, plus risks from dental capex cyclicality, currency swings and competition from Dentsply Sirona and Planmeca.
Teleflex (TFX) 2026 stock analysis: recurring single-use device revenue across catheters, vascular access, and UroLift, the planned separation of Urology, Acute Care and OEM, the BIOTRONIK vascular deal, UroLift's growth debate, and margins funding deleveraging.
Nordson (NDSN) 2026 stock analysis: the precision adhesive and coatings dispensing moat, the three-segment structure spanning electronics test and inspection and medical fluid components, why recurring consumables revenue cushions the cycle, NBS-driven M&A compounding, and the electronics-cycle and valuation risks.
Interojo (KOSDAQ 119610) stock outlook for 2026. A qualitative deep dive into its silicone hydrogel one-day and color contact lens ODM edge, the Clalen own-brand, export expansion into Japan, Europe and the Middle East, the capacity build cycle, and FX leverage for foreign investors.
Globus Medical (GMED) 2026 stock analysis: the ExcelsiusGPS razor-blade robotics model, NuVasive merger synergies versus sales-force disruption, trauma and orthopedics expansion, and heavyweight competition from Medtronic and Stryker.
Jeisys Medical (287410) 2026 stock outlook. A deep qualitative look at its RF and HIFU energy-based devices, the recurring consumable-tip revenue model, POTENZA export momentum, the three-way fight with Classys and Wontech, ownership and M&A risk, and the metrics that actually move this KOSDAQ aesthetic name.
InBody (KOSDAQ 041830) 2026 stock analysis for global investors: the world's leading body composition analyzer brand, B2B install base at hospitals and gyms, consumables and subscription recurring revenue, high overseas sales, net-cash balance sheet, and the FX, growth, and new-business risks.
West Pharmaceutical Services (WST) makes the stoppers, plungers, and seals inside injectable drug vials — and that regulatory design-in moat makes switching suppliers nearly impossible. Here's the long-term investment case, including biologics, GLP-1, and HVP mix tailwinds.
Align Technology (ALGN) 2026 stock analysis: Invisalign brand moat, iTero scanner razor-blade dynamics, patent expiry competition, teen expansion, and why this medtech trades like a consumer discretionary stock.